Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for nine companies, including New Element Pharmaceuticals, which is preparing for an IPO on the Hong Kong Stock Exchange [1] - New Element Pharmaceuticals is a biotechnology company established in 2012, focusing on developing therapies for metabolic, inflammatory, and cardiovascular diseases, particularly for gout patients [2] - The company has developed a core product, ABP-671, which has a unique chemical structure that eliminates liver toxicity risks compared to existing treatments, and is currently undergoing phase 2b/3 clinical trials in the US and China [2] Group 2 - The CSRC requested New Element Pharmaceuticals to clarify the reasons for inconsistencies in the identification of controlling shareholders and provide a conclusive legal opinion [1] - The CSRC also asked for details on new shareholders added in the last 12 months, including their reasons for investment, pricing, and any potential issues related to abnormal pricing or benefit transfer [1] - Additionally, the CSRC inquired whether the shares held by shareholders participating in the "full circulation" plan are subject to pledges, freezes, or other rights defects [1]
新股消息 | 新元素药业拟港股上市 中国证监会要求补充说明最近12个月内新增股东的基本情况等事项
智通财经网·2025-10-31 13:53